Tivic Health files Scorpius audited financials; FY2024 net loss $32.8M on $6.2M revenue

Valion Bio, Inc.

Scorpius FY2024 revenue $6.24M, net loss $32.8M; auditor BDO flags going-concern doubt due to recurring losses.
Scorpius total assets $39.2M, total liabilities $37.5M, stockholders' equity $1.7M at Dec 31, 2024.
Tivic sub Velocity Bioworks acquired all Scorpius assets on Dec 9, 2025, assuming no pre-closing liabilities.
Pro forma combined financials filed for Sep 30, 2025 and FY2024; combined company impact not quantified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.